Dynamic integration of skeletal muscle signals via extracellular vesicles in motor neuron diseases Authors: Flaminia Riggio, Gianmarco Fenili, Daniela Caporossi, Maria Paola Paronetto Published: 2026 ABSTRACT Extracellular vesicles (EVs) are heterogenous lipid bilayer-enclosed particles secreted by virtually all cell types. They encapsulate a diverse array of bioactive molecules, including proteins, lipids, nucleic acids, and metabolites, which can be transferred to recipient cells, thereby modulating their function and phenotype. In recent years, skeletal muscle-derived EVs (SkM-EVs) have emerged as key players in the bidirectional communication between skeletal muscle and motor neurons, contributing to the establishment and maintenance of neuromuscular homeostasis. Disruptions in this intercellular signalling have been implicated in the pathophysiology of motor neuron diseases (MNDs) such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). In these contexts, SkM-EVs may contribute to disease progression by delivering pathogenic cargo, including misfolded proteins and aberrant RNAs, to motor neurons. A comprehensive understanding of SkM-EV biology, particularly their roles in neuromuscular communication, could offer critical insights into disease mechanisms and identify novel opportunities for biomarker discovery and therapeutic intervention. This review synthesizes current knowledge on the functional roles of SkM-EVs in motor neuron health and disease and evaluates their potential as diagnostic tools and therapeutic vectors in the context of MNDs. Extracellular vesicles in the skeletal muscle-nervous systems crosstalk Background Extracellular vesicles (EVs) are small, lipid bilayer-enclosed particles released by a wide range of cell types that bear bioactive molecules (proteins, lipids, nucleic acids and metabolites) which can be transferred to recipient cells, modulating their function and behaviour [1]. Skeletal muscle-derived EVs (SkM-EVs) are emerging as key mediators of the high dynamic communication in muscle-motor neuron interaction [2]. EVs released from muscle cells can in fact modulate neuronal activity and contribute to neuromuscular homeostasis. Disruption in this communication deeply contributes to the pathogenesis of motor neuron diseases (MNDs), including spinal muscular atrophy, (SMA) and amyotrophic lateral sclerosis (ALS), where EVs may exacerbate neuronal degeneration and promote disease progression by transferring pathogenic molecules, such as misfolded proteins and dysregulated RNAs, to motor neurons [3]. Motor neurons (MNs) are specialized nerve cells whose cell bodies are located within the central nervous system (CNS), including the motor cortex, brainstem motor nuclei, and ventral horn of the spinal cord. Their axons extend into the peripheral nervous system (PNS), where they innervate skeletal muscles and transmit signals required for voluntary movement. MN axons are not merely passive conduits but function as autonomous compartments capable of local mRNA translation, which is essential for axonal maintenance, growth, and synaptic activity [4, 5]. Within this framework, EVs derived from skeletal muscle and glial cells have recently emerged as modulators of axonal biology. In particular, EV-associated miRNAs may influence local translational programs within axons and presynaptic terminals, thereby contributing to neuromuscular communication and potentially to disease mechanisms [6, 7]. The chemical synapses between MNs terminals and skeletal muscle fibers, named neuromuscular junctions (NMJs), are crucial for controlling muscle contraction. Depolarization of MNs triggers acetylcholine release at organized sites called active zones, leading to muscle fiber activation. Importantly, NMJ establishment and long-term maintenance rely on a tightly bidirectional communication between muscle and MNs. When this communication is altered, as it occurs in aging and pathological conditions, the muscle function becomes progressively compromised [8]. Such disturbances in neuromuscular signalling are increasingly recognized as key contributors to the onset and progression of MNDs. In ALS, the progressive degeneration of both upper and lower MNs, leads to muscle weakness, paralysis, and ultimately respiratory failure. ALS typically manifests in adulthood and is clinically and genetically heterogeneous - with ~ 90% of cases being sporadic and the remaining 10% familial - involving mutations in several genes such as SOD1, TARDBP, FUS, and C9orf72 [9]. Overall, ALS can be considered a complex and multifactorial pathology [10]. Oxidative stress is a key contributor, driving mitochondrial dysfunction, protein misfolding, DNA damage, and neuronal death. It also activates astrocytes and microglia, triggering neuroinflammation through the release of pro-inflammatory cytokines. Additionally, accumulation of protease-resistant misfolded proteins and toxic protein aggregates is a common mechanism in ALS. Another hallmark of ALS is glutamate excitotoxicity, where excessive glutamate levels cause further neuronal injury. ALS has traditionally been viewed as an MND, but recent evidence shows that non-neuronal cells also contribute to its progression [11]. The dying back hypothesis [12] suggests that ALS begins at the neuromuscular junctions, with muscle dysfunction preceding MN degeneration. In this context, EVs may play a key role in spreading disease signals, including toxic proteins and inflammatory factors. Muscle-derived EVs could be important in early disease stages, offering new perspectives on ALS development. SMA, on the other hand, is a monogenic autosomal recessive disease caused by deletions or mutations in the SMN1 gene, leading to reduced levels of survival motor neuron (SMN1) protein [13]. SMN deficiency leads to degeneration of α-motor neurons in the anterior horn of the spinal cord, causing progressive muscle atrophy, weakness, bulbar dysfunction, and respiratory insufficiency [13]. SMA type I accounts for approximately 50–60% of incident cases and represents the most severe phenotype, historically associated with death or permanent ventilatory dependence before 2 years of age. SMA types II, III, and IV show progressively milder phenotypes with later onset and greater preserved motor function [13]. Recent therapeutic advances, including SMN-enhancing approaches such as antisense oligonucleotides, gene replacement therapy, and small-molecule splicing modifiers, together with optimization of multidisciplinary supportive care, have substantially altered the natural history of the disease [13]. These interventions have improved survival, preserved motor function, and slowed disease progression across the SMA spectrum. Notably, beyond passive degeneration, skeletal muscle may actively contribute to disease progression through EV-mediated signalling, representing a key link between muscle pathology and MN dysfunction. A comprehensive understanding of the role of SkM-EVs and their interactions holds the potential to unveil the underlying physiological and pathological mechanisms through which muscles influence MNs. This, in turn, may lead to the identification of novel biomarkers and therapeutic strategies aimed at restoring their proper functioning. In this review, we provide an overview of the mechanisms underlying the impact of SkM-EVs on MN health and function, highlighting their role in muscle-MN communication and their contribution to the pathophysiology of MNDs. We lastly explore the diagnostic and therapeutic potential of EVs in the context of MNDs, their ability to serve as biomarkers and potential use in targeted delivery of therapeutic molecules. Classification, biogenesis and cargoes Intercellular communication is orchestrated through direct cell-cell contact or the release of soluble factors such as cytokines, growth factors, hormones, oligonucleotides, and various other biomolecules. EVs have been increasingly recognized as pivotal mediators in this complex signalling network, participating in the regulatory mechanisms of cell communication. First considered as a cellular waste disposal mechanism, EVs are now recognized to have a far more complex role in cell-cell communication, both in physiological and pathological conditions [14]. Although a unified nomenclature and classification system for EVs has yet to be established and there is still some controversy [15], they are commonly categorized into three primary subtypes, based on their size and biogenesis. Specifically, vesicles are typically classified into exosomes (30–150 nm), originating from the endosomal pathway, microvesicles (150 nm–1 μm), formed by budding from the plasma membrane, and apoptotic bodies (1000–5000 nm), derived from the fragmentation of a cell during the process of apoptosis [16]. In recent years, new subpopulations of EVs have been identified, including mitovesicles (derived from mitochondria, 30 nm–4 μm), migrasomes (released from actively migrating cells, 500 nm–3 μm) and oncosomes (released specifically from tumor cells, 1 –10 μm) [1, 17–19] (Fig. 1A). Fig. 1A Schematic representation of the main classes of EVs organized by size, ranging from small exosomes to larger EVs, including apoptotic bodies and oncosomes. Size ranges are approximate and overlap between subtypes. B Two main types of EVs are distinguished based on their biogenesis: exosomes and microvesicles. Exosomes are generated within the endosomal system through the inward budding of MVBs, which subsequently fuse with the plasma membrane to release these small vesicles into the extracellular space. Microvesicles arise from the outward budding and fission of the plasma membrane. These distinct biogenetic pathways result in differences in their molecular composition: surface protein profiles and content vary between the two EVs subtypes, reflecting their unique cellular origins and potentially influencing their targeting and functional roles in intercellular communication. ARF6: ADP-ribosylation factor 6. Figure created using BioRender A Schematic representation of the main classes of EVs organized by size, ranging from small exosomes to larger EVs, including apoptotic bodies and oncosomes. Size ranges are approximate and overlap between subtypes. B Two main types of EVs are distinguished based on their biogenesis: exosomes and microvesicles. Exosomes are generated within the endosomal system through the inward budding of MVBs, which subsequently fuse with the plasma membrane to release these small vesicles into the extracellular space. Microvesicles arise from the outward budding and fission of the plasma membrane. These distinct biogenetic pathways result in differences in their molecular composition: surface protein profiles and content vary between the two EVs subtypes, reflecting their unique cellular origins and potentially influencing their targeting and functional roles in intercellular communication. ARF6: ADP-ribosylation factor 6. Figure created using BioRender The classical process of exosome biogenesis involves the formation of multivesicular bodies (MVBs) by inward of the endosomal membrane which contain intraluminal vesicles (ILVs). In turn, MVBs can either fuse with lysosomes for degradation or with the plasma membrane to release ILVs, which are then released as exosomes [20]. This process requires extensive membrane remodelling, and the coordinated activity of several protein complexes refereed as endosomal sorting complexes required for transport (ESCRTs), which are essential for cargo selection and sorting [21]. During the MVB maturation, as first, membrane enriches of tetraspanins, particularly CD9 and CD63. Tetraspanins play a pivotal role in the organization of membrane structure, thereby facilitating the formation of microdomains, necessary for the establishment of ILVs and the efficient sorting of molecular cargo [21, 22]. A second step involves the recruitment of ESCRT complexes, which are comprised of four main subunits: ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III [23]. ESCRT-0 is the first complex which engages, recognizes and binds ubiquitinated cargo on the MVB membrane. Once ESCRT-0 has bound the ubiquitinated cargo, ESCRT-I and ESCRT-II are recruited to the cytosolic side of the MVB, where they interact to initiate membrane curvature and budding inward to form ILVs [24] (Fig. 1B). Subsequently, ESCRT-III is recruited by ALIX (programmed cell death 6 interacting protein) to complete the vesicle scission [25]. ALIX binds simultaneously to the TSG-101, a component of the ESCRT-1, and CHMP4, a component of the ESCRT-III [26]. Exosome secretion also requires the participation of the soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) complex [27]. Although the ESCRT pathway is considered the major mechanism of exosome formation, alternative pathways, including sphingolipid-mediated processes involving ceramide, may also contribute to exosome biogenesis [28, 29]. Unlike exosomes, microvesicles are generated by the direct outward budding and fission of the plasma membrane. This process involves extensive remodelling of the plasma membrane composition, with specific redistribution of phospholipids and proteins. A key feature is phosphatidylserine exposure on the outer leaflet of the membrane, regulated by calcium-dependent enzymes such as scramblases and translocases, which represents a hallmark of microvesicles formation and is critical for their recognition by recipient cells [30, 31]. Furthermore, the rearrangement of the underlying cytoskeleton, particularly the actin filaments, is required for membrane budding and release of microvesicles. Small GTPases are key regulators of this process, as they activate downstream signalling pathways that induce myosin light chain phosphorylation and cytoskeletal contraction [32, 33]. As a result of distinct biogenesis pathways involved in EV formation, it is possible to determine which proteins and lipids are incorporated into vesicles during their development and use them as specific marker of EV subpopulations. For instance, exosomes are often characterized by the tetraspanins CD63, CD9 and CD81, reflecting their origin from MVBs, whereas ALIX and TSG-101 reflect the implication of the ESCRT complex [21, 34]. Although microvesicles lack these well-established markers, they are sometimes characterized by ADP-ribosylation factor 6 (ARF6) and ANNEXIN-1 [33, 35]. Apoptotic bodies, instead, are commonly associated with markers like TSP and C3b [21]. However, it is important to note that some of these processes can overlap, and several markers may be shared among different vesicle subtypes. In addition, exosome formation can also occur through ESCRT-independent mechanisms, leading to the absence of canonical biomarkers [21]. These limitations challenge the accurate identification and characterization of EVs and underscore the need for more advanced and standardized methods for their characterization and discrimination. To date, several online databases are available, providing information about EVs (Table 1). These databases represent an invaluable compendium of useful information for researcher as they provide data about their composition, characteristics and functions. The protein cargo of EVs can be classified according to its role in vesicle biogenesis, release mechanisms, and functional activity [36]. In addition, EVs also carry proteins that are specific of their cell of origin, such as transcription factors and, in the case of tumour-derived EVs, protein associated with tumour progression, including those associated with metastasis, immune evasion and angiogenesis [37]. EVs usually mirror the lipid composition of the parent cell membrane, although exhibiting some unique characteristics. EV membranes are typically enriched in cholesterol, ganglioside GM3, phosphatidylserine, ceramide and sphingomyelin, like the plasma membrane of the parent cell [38], whereas phosphatidylcholine and diacyl-glycerol are decreased compared to the lipid membrane composition of the parental cell [39]. In addition to proteins and lipids, EVs also transport a diverse range of nucleic acids, that are crucial for cell-to-cell communication and are even able to reprogram the gene expression profile of recipient cells. EVs contain genomic DNA as well as mitochondrial DNA, which can be delivered to recipient cells, potentially influencing their activity [40–44]. While the precise mechanisms underlying DNA packaging into EVs remain unclear, the presence of DNA within these vesicles may play a significant role in supporting cellular homeostasis. The presence of DNA in the cytoplasm is often associated with cellular stress, DNA damage, or infection, events that can activate innate immune responses. The export of DNA via EVs may therefore serve as a protective mechanism to maintain cellular homeostasis by preventing inappropriate immune activation [43]. While the presence of DNA in EVs has garnered significant attention, it is arguably the RNA cargo that represents the most functionally relevant component. EVs contain various types of RNA, including mRNA, microRNAs (miRNAs), tRNAs, ribosomal RNAs, non-coding RNAs, small nuclear RNA, small nucleolar RNA, piwi-interacting RNA and circRNAs [45–49]. The RNA content differs across EV subpopulations [50] and plays a pivotal role in intercellular communication, modulating gene expression and reprogramming recipient cells, thereby contributing to both physiological and pathological processes. Table 1List of online EV databases. The table summarizes major online databases that catalogue data from EVs. The table reports the website, the EV types covered (including vesicle class), the cargo described, data source and the analytical tool provided (if any)WebsiteType of EVsData typeData sourcesAnalysis toolsCitationExoCarta http://www.exocarta.org Exosomes from eukaryotesRNA, proteins, lipidsPublished and unpublished exosomal study – manually curatedGO-based annotations, PPI and graphical molecular networks, enrichment analysis-No integrated interactive analysis tools[51]EVpedia http://evpedia.info All classes EVs from both prokaryotes and eukaryotesRNA, proteins, lipidsHigh-throughput datasetGO enrichment analysis, network analysis and set analysis of vesicular components[52]Vesiclepedia http://www.microvesicles.org/ All classes of EVs from both prokaryotes and eukaryotesRNA, DNA, proteins, lipids, metabolitesPublished study – manually curatedExternal annotations and resources, without internal analytical tools[53]EV-ADD https://www.evdnadatabase.com/ EVs from human liquid biopsy samples and in vitro studiesEV-associated DNASystematic review of literature (up to June 2022) – manually curatedNo internal analytical tools[54]EVmiRNA https://guolab.wchscu.cn/EVmiRNA/#!/ Exosomes and microvesiclesEV-associated miRNAsSmall RNA-seq datasets of EVs in different tissues/diseasemiRNA expression levels, function, pathway regulations, target regulations and drug’s effect on miRNA[55]EVAtlas https://guolab.wchscu.cn/EVAtlas/#/ Human EVsEV-associated ncRNA (miRNA, snoRNA, piRNA, snRNA, rRNA, tRNA, Y RNA)Small RNA-seq datasets of EVs in different tissues/diseaseGene location, expression profiles potential functions, target regulations, related drugs[56] Table 1List of online EV databases. The table summarizes major online databases that catalogue data from EVs. The table reports the website, the EV types covered (including vesicle class), the cargo described, data source and the analytical tool provided (if any)WebsiteType of EVsData typeData sourcesAnalysis toolsCitationExoCarta http://www.exocarta.org Exosomes from eukaryotesRNA, proteins, lipidsPublished and unpublished exosomal study – manually curatedGO-based annotations, PPI and graphical molecular networks, enrichment analysis-No integrated interactive analysis tools[51]EVpedia http://evpedia.info All classes EVs from both prokaryotes and eukaryotesRNA, proteins, lipidsHigh-throughput datasetGO enrichment analysis, network analysis and set analysis of vesicular components[52]Vesiclepedia http://www.microvesicles.org/ All classes of EVs from both prokaryotes and eukaryotesRNA, DNA, proteins, lipids, metabolitesPublished study – manually curatedExternal annotations and resources, without internal analytical tools[53]EV-ADD https://www.evdnadatabase.com/ EVs from human liquid biopsy samples and in vitro studiesEV-associated DNASystematic review of literature (up to June 2022) – manually curatedNo internal analytical tools[54]EVmiRNA https://guolab.wchscu.cn/EVmiRNA/#!/ Exosomes and microvesiclesEV-associated miRNAsSmall RNA-seq datasets of EVs in different tissues/diseasemiRNA expression levels, function, pathway regulations, target regulations and drug’s effect on miRNA[55]EVAtlas https://guolab.wchscu.cn/EVAtlas/#/ Human EVsEV-associated ncRNA (miRNA, snoRNA, piRNA, snRNA, rRNA, tRNA, Y RNA)Small RNA-seq datasets of EVs in different tissues/diseaseGene location, expression profiles potential functions, target regulations, related drugs[56] List of online EV databases. The table summarizes major online databases that catalogue data from EVs. The table reports the website, the EV types covered (including vesicle class), the cargo described, data source and the analytical tool provided (if any) GO-based annotations, PPI and graphical molecular networks, enrichment analysis - No integrated interactive analysis tools EV functions EVs are present in almost all biological fluids, and their release occurs from a wide range of cell types influencing cellular function and behaviour by contact, like ligand/receptor contact, or by internalization of contents, either with endocytosis into target cells or by fusion with their plasma membrane [57]. Interestingly, EV secretion and molecular composition dynamically change to maintain homeostasis, providing valuable insight into the health of specific tissue, organs, or the entire individual [58]. This makes them a promising biomarker for assessing health conditions, detecting diseases, and monitoring therapeutic interventions. Through the transfer of signalling molecules and genetic material from one cell to another, EVs serve as important mediators of intercellular communication, and regulates a wide range of cellular processes, including gene expression, cellular metabolism and tissue regeneration [59–62]. For instance, EVs derived from mouse embryonic stem cells have been shown to promote self-renewal and expansion of adult stem cells thanks to the transfer of specific mRNAs [63]. This suggests that the mRNAs contained into the EVs are indeed functional and ready to be translated in the recipient cells, impacting differentiation pathways and potentially reversing or modifying cell identity [64]. Jung and colleagues showed that EVs released during the differentiation of stem cells into white or beige adipocytes can drive cellular reprogramming by transferring miRNAs [64]. This finding paves the ground for further exploration aimed at modulating cellular plasticity and reprogramming by EVs, thus offering potential therapeutic applications across various fields. Within the nervous system, EVs have been implicated in the maintenance of homeostasis, participating in waste clearance, synaptic plasticity and trophic support for neurons [65]. Although this review primarily focuses on skeletal muscle-derived EVs, EVs released by glial cells also warrant brief discussion due to their important roles in neural repair and regeneration. Glial cell-derived EVs exert different effects depending on their cellular origin: astrocyte-derived EVs can modulate neuronal survival and inflammation, microglial EVs regulate immune responses, whereas oligodendrocyte- and Schwann cell-derived EVs support axonal maintenance, myelin clearance, and nerve regeneration [66, 67]. To this regard, it was reported that Schwann cell-derived exosomes markedly enhanced axonal regeneration in a sciatic nerve injury model through suppression of the GTPase RhoA pathway [68]. Likewise, exosomes derived from Schwann cells facilitated functional recovery following spinal cord injury in rats [68]. During nerve repair, the exosomal transfer of specific miRNAs appears to modulate Schwann cell behaviour and phenotype. One example is represented by miR-182, which negatively regulates Schwann cell proliferation and migration [69]. After nerve injury, increased miR-182 expression may be transferred between Schwann cells via exosomes, where it suppresses fibroblast growth factor 9 (FGF9) and neurotrimin (NTM). These preclinical findings have activated initial steps toward clinical translation. A recent case study documented the administration of allogeneic Schwann cell-derived exosomes (SC-EXOs) in a patient with ALS to promote MN preservation [70], highlighting the increasing interest in the potential use of SC-EXOs and related EVs for neurodegenerative diseases. Skeletal muscle-derived EVs Beyond its essential function in locomotor activity, skeletal muscle is also recognised as a secretory organ that modulates both local and systemic physiological processes [71], with SkM-EVs as potent mediator of this communication [2]. SkM-EVs, released under basal conditions as well as upon physiological stimuli such as exercise and muscle regeneration [72], can impact on tissue metabolism and regenerative processes, contributing to the coordination of muscle function and adaptation. Remarkably, SkM-EVs can also impact on muscle myogenesis, regeneration and repair by regulating muscle satellite cells [2, 73]. Also in the recipient cells, SkM-EVs can modulate the expression of genes involved in muscle regeneration and differentiation, such as MyoD, myogenin and Pax7 [2, 73], or they can carry these myogenic growth factors themselves. Choi and colleagues demonstrated that exosomes released by differentiating human skeletal muscle cells carry various bioactive factors, including heparin-binding EGF-like growth factors (HB-EGFs), vascular endothelial growth factor (VEGFs), insulin-like growth factors (IGFs), IGF-binding protein 3 (IGFBP-3), fibroblast growth factor 2 (FGF2), Interleukin 6 (IL6), and neurotrophin 3, which promote myogenic differentiation of stem cells in vitro and play a role in the regeneration of skeletal muscle tissue in vivo [74]. Nakamura and colleagues demonstrated that EVs derived from mesenchymal stem cells (MSCs) enhance angiogenesis and myogenesis in vitro and promote muscle regeneration in an experimental muscle injury model in mouse [75]. Similarly, C2C12-derived exosomes injected into the gastrocnemius muscle of injured mice can promote damage repair by triggering muscle regeneration [76]. In addition to canonical EV markers such as ALIX, CD81 and Flotillin-1, skeletal SkM-EVs contain muscle-associated proteins including ATP2A1, β-enolase, calsequestrin, caveolin-3 and desmin. Among them, ATP2A1, β-enolase and desmin have emerged as particularly promising SkM-EV markers due to their predominant expression in skeletal muscle tissue and their consistent detection in EV preparations [77]. However, increasing evidence suggests that the identification of truly skeletal muscle-specific markers of EVs remains challenging. Canonical EV markers such as CD63, CD9 and CD81 are broadly expressed across multiple cell populations within skeletal muscle and may predominantly localize in the interstitial non-myofiber cells rather than in the myofibers themselves. Moreover, proposed SkM-EV markers, including α-sarcoglycan, ATP2A1, β-enolase and desmin are not entirely specific to skeletal muscle, as also expressed in the cardiac tissue [78, 79]. These findings highlight the substantial heterogeneity of EV populations within skeletal muscle and underscore the current lack of definitive markers able to unequivocally identify circulating SkM-EVs in vivo. Among the EV cargoes involved in muscle regeneration and differentiation, miRNAs play a critical role. During myoblast differentiation, a selective repertoire of miRNAs is upregulated and enclosed into EVs, contributing to the maintenance of muscle homeostasis. It was shown that C2C12-derived EVs are critically involved in the regulation of muscle differentiation and regeneration, through the upregulation of miR-1, miR-133b and the downregulation of mir-381 and miR-93, involved in cell proliferation and differentiation [80, 81]. One proposed mechanism underlying the activity of these EV-associated miRNAs involves the downregulation of sirtuin-1 [81], able to modulate both the myogenic differentiation program, and the mitochondrial biogenesis and fatty acid oxidation [82, 83]. This evidence supports the notion that EV-mediated transfer of miRNAs and other molecules may act as a finely tuned regulatory axis influencing key aspects of muscle cell fate and metabolic adaptation. Fluorescently labelled SkM-EVs injected into mice can reach multiple organs, such as lungs, liver, spleen, brain, heart, and pancreas, supporting the idea that SkM-EVs may serve as mediators of the crosstalk between skeletal muscle and other organ systems [84]. Remarkably, the distribution of miRNAs within exosomes differs depending on the muscle fiber composition of each muscle type [80]. Exosomes released from five different skeletal muscles (extensor digitorum longus, tibialis anterior, gastrocnemius, soleus and quadriceps) carried the four muscle-specific microRNAs (myomiRs): miR-1, miR-133a, miR-133b, and miR-206. In most muscle types, exosomes contained higher levels of miR-1, miR-133a, and miR-133b than miR-206. However, exosomes derived from the soleus carried higher amounts of miR-206 and lower levels of miR-1 compared with exosomes from the other muscles [80]. These findings suggest that the loading of myomiRs into exosomes is not simply determined by their abundance inside the muscle cells. Instead, selective mechanisms appear to regulate which myomiRs are packaged into exosomes. Given their close anatomical and functional integration, skeletal muscle and bone engage in dynamic crosstalk, wherein mechanical stimuli are converted into biochemical signals and systemic endocrine responses. Emerging evidence highlights EVs as critical mediators in this mechano-transductive communication, facilitating the exchange of regulatory molecules between these two tissues. EVs from healthy muscle can support osteogenic differentiation of marrow stromal/stem cells (BMSCs) and suppress osteoclast formation [85], while EVs from atrophic muscle have opposite, detrimental effects [85]. SkM-EVs also deliver enzymes and miRNAs that regulate bone metabolism and repair [86, 87]. Communication between skeletal muscle and the cardiovascular system is well-studied due to their involvement in various diseases. Several studies have demonstrated the cardioprotective effects of SKM-EVs in dystrophic and heart failure models. In mdx mice, EVs from allogeneic myogenic progenitor cells improved cardiac function, potentially through anti-apoptotic and anti-inflammatory mechanisms, as indicated by increased BCL-2 and reduced IL-6 levels [88]. In a related study, cardiosphere-derived EVs enhanced dystrophin expression in skeletal muscle, possibly via transfer of miR-148a [89]. Additionally, remote limb ischemic conditioning was shown to stimulate the release of SKM-EVs enriched in musclin, CD71, VEGF, and β2-adrenergic receptor, which contributed to improve cardiac function in a mouse model of heart failure [90]. Exercise promotes the release of SkM-derived EVs carrying protective molecules that activate heart-protective pathways [91]. In this regard, specific miRNAs altered in heart failure have been identified as potential mediators of heart-muscle communication [90]. Furthermore, skeletal muscle fibers regulate the surrounding endothelial cells (EC) via secretion of numerous angiogenic factors in SkM-EV. EVs released from oxidative muscle fibers are produced in greater amounts and exert stronger pro-angiogenic effects on endothelial cells, including enhanced tube formation and migration in mice, compared with EVs derived from glycolytic fibers [92]. Moreover, oxidative fiber-derived EVs (OXI-EVs) carry miRNAs that more effectively promote angiogenic signalling pathways than glycolytic fiber EVs (GLY-EVs) [92]. Overall, SkM-derived EVs play key roles in cardiovascular and vascular health through intercellular signalling. EV-mediated signalling in muscle-nerve communication Skeletal muscle sends retrograde signals to MNs, essential for the formation and maintenance of NMJ and proper motor unit function. The NMJ represents specialized chemical synapse that connects MNs to skeletal muscle fibers. Upon activation, MNs release neurotransmitters that bind to receptors on the muscle surface, initiating muscle contraction and contributing to the maintenance of muscle homeostasis. In parallel, skeletal muscle provides retrograde signals that support NMJ plasticity and sustain MN function [3, 93]. Classical muscle-derived retrograde factors include neurotrophins, such as brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), IGF-1, and FGFs, all of which contribute to MN function and axonal stability. Neural denervation, commonly associated with aging, chronic inflammation, and neuromuscular disorders, disrupts this bidirectional communication, ultimately leading to progressive muscle weakening (Fig. 2). In vitro studies have shown that EVs secreted by muscle cells can enhance MN survival and neurite outgrowth [94]. In vivo, muscle denervation prompts the release of SkM-EVs, that play a key role in ensuring correct MN regeneration in rats [95]. Huang et al. have recently demonstrated the important bidirectionality in muscle-MN communication, showing how neuronal innervation plays a key role in competing skeletal muscle secretory activity. Their study revealed that innervated muscle increased secretion of exosomes carrying miRNA cargo involved in nervous system, such as miR-206, miR-9-5p and let-7, which are associated with neuroprotective effect, NMJ integrity and neurogenesis [93, 96]. Overall, neuronal activity shapes the secretory profile of skeletal muscle, enhancing the release of neurotrophic factors and specific miRNA-loaded EVs. Conversely, denervation induces muscle degeneration and alters EV composition, impairing muscle homeostasis and communication [2]. In this regard, in a neuromuscular tissue model with SkM functionally innervated by MNs, researchers observed enhanced expression of neurotrophic myokines, including IL-6, BDNF, and fibronectin type III domain-containing protein 5 (FNDC5) [93], whereas glutamate stimulation promoted the release of Irisin and EVs enriched with a broader spectrum of neurotrophic miRNAs compared to non-innervated muscle [97]. Nerve injury triggers rapid muscle fiber degeneration through activation of atrophy pathways and sarcomere breakdown, paralleled by substantial changes in the miRNA loading on SkM-EVs, with elevated miR-206 level and diminished miR-1 and miR133a/b [98]. The uptake by neuronal SH-SY5Y cells of C2C12-derived EVs enriched of miR-29b-3p led to the downregulation of neuron-specific genes and the consequent inhibition of neuronal differentiation [99]. Importantly, EV-mediated signalling appears to operate bidirectionally at the NMJ. Studies from Vivian Budnik and colleagues demonstrated that MN-derived EVs participate in synaptic communication and influence postsynaptic organization [100, 101]. Meanwhile, SkM-EVs can directly affect MN biology, including neurite outgrowth, axonal maintenance, and stress responses [102]. To this regard, accumulating evidence suggests that RNA localization and local translation are highly compartmentalized at the NMJ. In this context, Denes and colleagues demonstrated selective RNA compartmentalization at the postsynaptic apparatus, raising the intriguing possibility that EV-mediated RNA transfer may contribute to local signalling processes at the neuromuscular synapse [103]. Additionally, muscle specific miRNAs of the mir-1/206/133 family are responsible for NMJ stability, regulating the DOK7-CRK–RAC1 signalling cascade in mice. These miRNAs fine-tune the pathway by repressing CRK, thereby maintaining appropriate RAC1 activity levels. When this regulation is disrupted, RAC1 signalling becomes imbalanced, resulting in NMJ dysfunction and severe neuromuscular impairments [104, 105]. Although direct evidence for selective EV-RNA shuttling across the NMJ remains limited, this mechanism represents a promising area for future investigation. Notably, physical exercise could have a significant positive impact on NMJs by stimulating skeletal muscle. Specifically, physical exercise has increasingly been recognized as a complementary therapeutic strategy for neurodegenerative disorders, largely because of its anti-inflammatory effects [106–108]. Recent evidence indicates that EVs released during physical exercise carry anti-inflammatory exerkines, that may significantly contribute to inter-organ communication and help mediate the beneficial physiological effects of physical activity [109]. In particular, EVs released in response to physical exercise have been shown to attenuate inflammagen-induced microglial activation, highlighting their potential as therapeutic tools for neuroinflammatory disorders [110]. The underlying mechanism involves the attenuation of NF-κB activation [110]. Notably, in a mouse model of ALS carrying mutant SOD1, blocking NF-κB signalling in microglia protected MNs and increased survival [111]. Furthermore, in spinal cord tissue from sporadic ALS patients, TDP-43 colocalizes with the NF-κB p65 subunit in microglia, indicating a potential role of the canonical NF-κB pathway in TDP-43 dysregulation [112]. These findings highlight the relevance of targeting microglial NF-κB signalling to reduce inflammation-driven neurodegeneration and suggest that EVs associated with physical activity may represent a promising, naturally derived strategy to help counteract neurodegenerative disorders. However, to date, there is limited experimental evidence on the effects of physical exercise on the NMJ mediated by EVs. Assumptions about its beneficial effect are mainly based on studies of the content of EVs released into the bloodstream [113]. Fig. 2Potential implications of EVs on MN physiology. On the left, a normal physiological condition is depicted, characterized by healthy SkM. The composition of SkM-EVs includes miRNAs and neurotrophins, that have been shown to regulate and support NMJ integrity, MN survival, neurogenesis, and neurite outgrowth. On the right, the ALS pathological condition is illustrated. During disease progression, SkM-EVs carry miRNAs and misfolded proteins that contribute to neuronal degeneration, including NMJ dismantling and induction of cell death, ultimately leading to denervation. This pathological cascade further impairs neuronal differentiation, as evidenced reduced neurite outgrowth and decreased branching complexity. Figure created using BioRender Potential implications of EVs on MN physiology. On the left, a normal physiological condition is depicted, characterized by healthy SkM. The composition of SkM-EVs includes miRNAs and neurotrophins, that have been shown to regulate and support NMJ integrity, MN survival, neurogenesis, and neurite outgrowth. On the right, the ALS pathological condition is illustrated. During disease progression, SkM-EVs carry miRNAs and misfolded proteins that contribute to neuronal degeneration, including NMJ dismantling and induction of cell death, ultimately leading to denervation. This pathological cascade further impairs neuronal differentiation, as evidenced reduced neurite outgrowth and decreased branching complexity. Figure created using BioRender SkM-EVs in MND The interplay between muscle and MNs becomes particularly relevant in the context of MNDs. MNDs encompass a group of neurodegenerative disorders characterized by the progressive degeneration of upper and/or lower MNs, resulting in muscle weakness and atrophy. MNDs are classified as either heritable or sporadic, and by the degree of upper or lower MN involvement, ranging from pure lower MN syndromes, to mixed upper and lower MN diseases; to pure upper MN diseases [114]. ALS and SMA represent the two major forms of MNDs [115], each representing distinct paradigms of adult and paediatric onset motor-neuron pathology, respectively. Despite their differences in age of onset, genetic aetiology, and disease progression, ALS and SMA share several pathophysiological features that drive and/or exacerbate to MN degeneration [116]. These include impairments in RNA metabolism, alteration of axonal transport, mitochondrial dysfunction, and synaptic alterations at the NMJ. In ALS, mutations in RNA-binding proteins, including TDP-43, FUS, heterogeneous nuclear ribonucleoproteins A1, hnRNPA1 and hnRNPA2B1, as well as Senataxin, lead to aberrant RNA transcription, processing and transport and to abnormalities in the metabolism of noncoding RNAs and miRNA biogenesis, ultimately affecting MNs [117–121]. In SMA, the reduction of SMN1 protein impairs the assembly of the small nuclear protein (snRNP), essential for pre-mRNA splicing, thus causing widespread splicing defects [122]. Mitochondria are central to cellular energy metabolism and redox homeostasis. In ALS, mitochondrial dysfunction is evident, with reduced activity of electron transport chain complexes and increased reactive oxygen species (ROS) production, leading to oxidative damage [123]. Similarly, in SMA, mitochondrial abnormalities, including impaired oxidative phosphorylation, contribute to increased ROS levels and cellular energy deficit [124]. Chronic neuroinflammation is a hallmark of ALS, characterized by the activation of microglia and astrocytes, leading to the release of pro-inflammatory cytokines such as TNF-α and IL-6, which exacerbate neuronal injury [10]. While less prominent in SMA, emerging evidence suggests that neuroinflammatory processes may also play a role in SMA pathogenesis [13]. Historically, the pathogenesis of these diseases has been thought of as a primarily neuronal process, with MN loss being considered the initiating event leading to muscle atrophy. Loss of motor stimulation, in facts, leads to muscle dysfunction, characterized by weakness and atrophy. However, in recent years this neurocentric view has been questioned [10]. As previously mentioned, skeletal muscle itself exerts retrograde influence on MN health and survival, with EVs representing a key mediator involved in the maintenance and remodelling of NMJ. Disruptions in muscle homeostasis may compromise this signalling, ultimately affect MN function and viability and potentially shape their vulnerability in disease. A recent study focusing on exosomes derived from atrophied C2C12 myotubes have shed light on how muscle atrophy may negatively impact neurons. These exosomes carry miRNAs, particularly miR-29b-3p, that appear to inhibit neuronal differentiation and reduce neurite length [99]. Accordingly, muscle is precociously affected in SOD1-G93A mouse models, before the onset of the disease and the first neuro-motor symptoms, showing cell autonomous defects [125]. This observation was confirmed in iPSC-derived human muscle model from healthy subjects and ALS patients, recapitulating ALS-related defects [126]. Myoblasts harbouring the SOD1-G93A mutation showed impaired fusion, forming shorter, smaller myotubes with disorganized contractile proteins and reduced receptor expression, leading to weakened and less synchronized contractions alongside mitochondrial dysfunction [126]. These findings supports a direct role of skeletal muscle in NMJ impairment [125, 126]. One primary characteristic in ALS is the degeneration of NMJs, which occurs well before an evident MN loss [127]. Furthermore, ALS mouse model that specific overexpress the mutated SOD1 only in skeletal muscle recapitulate the disease phenotype [128, 129] and, even in the absence of denervation, skeletal muscle fibres in patients with ALS still exhibit signs of dysfunction and atrophy [130]. This phenotype may be explained by impaired signalling involved in neuromuscular synapse maintenance within ALS patient muscle cells, with EVs playing a pivotal role in this process. Two studies have indeed demonstrated that skeletal muscle appear to be a potential source of vesicles-mediated toxicity in ALS. EVs from biopsy-derived myotubes of ALS patients impair neurites growth and branching and cause a cell death when administered to culture MN [35, 131]. A possible molecular mechanism underlying these processes could be the alteration of the FUS pathway, as proteomic analysis of these EVs revealed higher level of molecular partners binding FUS, such as RPL5 and caprin 1 [131]. Anakor and colleagues also observed a mild activation of human iPSC-derived astrocytes, in the form of increased branching, when treated with muscle exosomes from patients with ALS [35], whereas SkM-EVs from healthy individuals displayed a protective effect, enhancing MN viability. As discussed before, miRNAs packaged within EVs have emerged as important modulator of NMJ homeostasis. Under pathological condition, alterations in EV-associated miRNA profiles may alter signalling pathways and promote neurodegeneration. Ionescu and colleagues [102] observed that a reduction in SkM-EV miR126a-5p in the muscle of SOD1-ALS mouse models promotes abnormal protein synthesis at the NMJ, contributing to neurodegeneration. Conversely, miR126a-5p expression promotes neuroprotective effects by limiting TDP-43 accumulation and delaying motor symptom onset. Notably, EVs from regenerating muscle derived from cardiotoxin injection (CTXD14SkM-EVs) can counteract muscle atrophy of SOD1-G93A mice. These EVs promote muscle regeneration, reduce inflammation by shifting macrophages to an anti-inflammatory state, and suppress NF-κB pathway linked to protein degradation [132]. Importantly, some ALS-associated mutations directly affect EV biogenesis and cargo trafficking pathways. Mutations in CHMP2B, a core component of the ESCRT-III complex, impair ILV formation and MVB maturation, leading to defective EV secretion and endosomal accumulation [133]. Similarly, C9orf72 mutations disrupt Rab-dependent endosomal trafficking (Rab1, Rab5, Rab7, Rab11) and autophagy-lysosome function, indirectly altering EV release and composition [134]. Furthermore, some RNA-binding proteins implicated in ALS, including TDP-43, FUS, and hnRNPA2B1, regulate RNA metabolism and selective miRNA loading into EVs, thereby linking defects in RNA processing to aberrant EV cargo composition and intercellular propagation of toxicity. The alterations in SkM-EVs described in ALS condition are summarized in Table 2. These findings suggest that SkM-EVs hold therapeutic potential for treating muscle degeneration in ALS and that dysregulation of EV biogenesis, cargo sorting, and release pathways is not merely a consequence of neurodegeneration but may actively contribute to disease progression. This concept has been less clearly defined in SMA, partially due to its different aetiology and experimental accessibility. Given its monogenic and well-defined origin, muscle alteration in SMA has traditionally been viewed as a secondary consequence of the loss of SMN in neuron. However, studies have explored the role of muscle in SMA pathogenesis, indicating that damage at NMJ could represent a primary event in SMA [135–137]. Moreover, Muscle-specific depletion of SMN in animal models of SMA results in disrupted myogenesis and impaired NMJ functionality, suggesting that skeletal muscle is not merely a downstream target but may actively contribute to disease progression [138]. In vitro nerve-muscle co-culture model using healthy MNs and satellite cells derived from type I and type II SMA patients, showed degeneration of innervated muscle fibers within 1 to 3 weeks, suggesting a direct pathological contribution of muscle tissue in the more severe forms of SMA [139]. Interestingly, this degeneration was not observed when muscle cells from patients with other neurodegenerative disorders, including ALS, were used [140]. Nevertheless, the role of EVs muscle-MN crosstalk in SMA remains largely underrepresented in the current literature. While EVs have been studied as potential biomarkers and as vehicles for molecular delivery in SMA patients, the specific contribution of SkM-EVs release remains largely unexplored. Table 2Alterations of SkM-EVs in ALS diseasePathologicalcontextOriginCargo / EV alterationEV-related mechanismFunctional outcomeReferenceNerve injurySkeletal muscle (denervated)miR-206 up-regulationPathological EV cargo selectionNMJ repair and reinnervation [98]Nerve injurySkeletal muscle (denervated)miR-133b down-regulationPathological EV cargo selectionNMJ disfunction and neuromuscular impairment [98]Nerve injurySkeletal muscle (denervated)miR-1 down-regulationPathological EV cargo selectionNMJ disfunction and neuromuscular impairment [98]Atrophied muscleSkeletal musclemiR-29b-3p up-regulationPathological EV cargo selectionInhibition of neuronal differentiation [99]ALSCNSTDP-43, SOD1, FUS up-regulationEV-mediated secretion of misfolded proteinsPrion-like propagation of toxicity [131, 131, 141–143]ALSSkMmiR-126a-5p up-regulationAltered protein synthesis at NMJ, neurodegeneration [102]ALSNeurons / gliaRNA dysregulationC9orf72 → Rab1/5/7/11 trafficking defectsImpaired EV release and autophagy dysfunction [134]ALSNeuronsCHMP2B mutationESCRT-III dysfunction.Alteration in EV biogenesis and secretion. [133] Table 2Alterations of SkM-EVs in ALS diseasePathologicalcontextOriginCargo / EV alterationEV-related mechanismFunctional outcomeReferenceNerve injurySkeletal muscle (denervated)miR-206 up-regulationPathological EV cargo selectionNMJ repair and reinnervation [98]Nerve injurySkeletal muscle (denervated)miR-133b down-regulationPathological EV cargo selectionNMJ disfunction and neuromuscular impairment [98]Nerve injurySkeletal muscle (denervated)miR-1 down-regulationPathological EV cargo selectionNMJ disfunction and neuromuscular impairment [98]Atrophied muscleSkeletal musclemiR-29b-3p up-regulationPathological EV cargo selectionInhibition of neuronal differentiation [99]ALSCNSTDP-43, SOD1, FUS up-regulationEV-mediated secretion of misfolded proteinsPrion-like propagation of toxicity [131, 131, 141–143]ALSSkMmiR-126a-5p up-regulationAltered protein synthesis at NMJ, neurodegeneration [102]ALSNeurons / gliaRNA dysregulationC9orf72 → Rab1/5/7/11 trafficking defectsImpaired EV release and autophagy dysfunction [134]ALSNeuronsCHMP2B mutationESCRT-III dysfunction.Alteration in EV biogenesis and secretion. [133] Alterations of SkM-EVs in ALS disease ESCRT-III dysfunction. Alteration in EV biogenesis and secretion. The diagnostic and therapeutic potential of EVs Traditional diagnostic approaches for neurodegenerative disease, such as clinical assessment and neuroimaging, do not always enable accurate differential diagnosis, especially when distinguishing between phenotypically similar disorders. Furthermore, conventional tests often fail to allow early diagnosis and by the time a patient is diagnosed, levels of neurodegeneration are already severe, limiting their utility in early intervention strategies [144]. This call for an urgent need to identify clinically relevant biomarkers. EVs represent a promising class of biomarkers in MNDs. Their presence in almost all easily accessible biological fluid, such as blood, urine, saliva, breast milk and cerebrospinal fluid, and their ability to transport proteins, lipids and nucleic acid specific to their cell of origin, make them ideal candidates as non-invasive biomarkers that reflect the body physiological and pathological state. For instance, the presence and concentration of protein aggregates within EVs may provide valuable insights into the stage of disease progression [145]. Furthermore, distinct miRNA expression profiles have been identified in EVs derived from patients with neurodegenerative diseases compared to healthy individuals. In Alzheimer’s Disease, neuronal-derived exosomes isolated from peripheric blood have been shown to contain elevated amount of pathological phosphorylated tau and amyloid-beta, thus reflecting disease severity [146]. Similarly, in Parkinson disease (PD), exosomal alpha-synuclein has been detected at high concentrations in patient compared to healthy subjects [147]. Importantly, the quantification of exosomal alpha-synuclein has also been leveraged to discriminate PD from multiple system atrophy (MSA) [148]. Saucier and colleagues demonstrated that miRNAs profiles of plasma-derived EVs in patients with ALS differ significantly from that of healthy subjects [149]. Notably, two of the deregulated miRNAs, miR-15a-5p and miR-193a-5p-, have been associated with disease progression and clinical phenotype [149]. Later work based on proteome and RNA profiling of EVs from frontal cortex, spinal cord and serum of sporadic patients with ALS, reported altered EV size and dysregulated miRNA profiles across these tissues [150]. In patients with SMA, proteomic analysis of EVs released from fibroblasts revealed significant protein alterations, especially in regulators of the Wnt signalling pathway and in the Cajal bodies, as well as alteration in the levels of the insulin growth factor binding protein-3, highlighting the role of EVs as a promising source for SMA biomarkers [151]. A recent study also suggested EVs as possible biomarker for monitoring the response to Nusinersen treatment in SMA treatment, due to the presence of SMN transcript [152]. Despite this promise, several challenges remain. The lack of standardized protocols for EV isolation, characterization, and cargo analysis often complicates the comparability across different studies and patient cohorts. It is essential to overcome these limitations before EV-based diagnostic can become routine in clinical practice. EVs have garnered significant attention in recent years not only for their potential as diagnostic biomarkers, but also as therapeutic delivery vehicles. Given their ability to cross the blood-brain barrier (BBB) and to protect their cargo from enzymatic degradation in the bloodstream, thereby enhancing their stability and bioavailability, EVs can be useful for delivering therapeutic drugs to the CNS. Through genetic engineering techniques, EV peptide ligand surface can be modified, thus allowing the integration of further fusion proteins to enhance targeting specificity [153]. Despite these promising features, recent research has highlighted several limitations that continue to restrict the clinical application of EVs. No universal, reproducible procedure has yet been established to effectively load diverse cargo types into EVs and their limited loading capacity poses significant challenges in designing therapeutic applications. Beyond cancer, EVs also show significant promise for treating neurological disease. Intranasal administration of exosomes derived from MSCs have been demonstrated to ameliorate autistic-like behaviours in mice [154]. Cooper and colleagues highlight the therapeutic potential of engineered exosome delivery of siRNA, demonstrating their ability to reverse brain alpha-synuclein pathological condition [155]. EV-mediated transport of dopamine has been shown to increase its distribution into the brain, while minimizing toxicity if compared with free dopamine administration. These findings suggest that blood-derived EVs have the potential to serve as a promising drug delivery platform for targeted therapy against PD and other disease of the central nervous system [156]. Many studies also focus on the potential therapeutic applications of stem cell-derived EVs in MNDs, especially in ALS [157–159], whereas the possible use of SkM-EVs remains largely unexplored. Finally, although EVs can cross the BBB, the exact mechanisms, timing and condition under which this occurs remain subjects of ongoing investigations [160]. Determining how EVs pass through the BBB could open new therapeutic avenues for strategies aimed at targeted drug delivery and gene therapy in the CNS. As a result, there is growing interest in exploring EVs both as potential mediators and biomarkers of neurological pathology [161]. In conclusion EVs represent a promising frontier in both the diagnosis and treatment of various diseases. While numerous studies have demonstrated their potential, several challenges remain. Nonetheless, ongoing research and technological advances continue to push the boundaries of EV applications, bringing us closer to realizing their full clinical potential. Conclusions Emerging research increasingly highlights the critical role of EVs in both the normal functioning of the CNS and in the development of neurodegenerative conditions. Despite this growing recognition, much of our current understanding is derived from in vitro studies, as existing technologies are still inadequate for reliably tracking EVs and their dynamics in vivo. Developing precise tools to manipulate EVs release or uptake within the CNS, especially in live animal models, would represent a significant breakthrough. The release of guidelines from the MISEV (minimal information for studies of EVs) could help in reaching such advances, enabling researchers to uncover the roles of EVs in physiological and pathological contexts, potentially in a cell-type-specific manner [162]. However, this goal remains out of reach due to the limited specificity of current genetic models and the incomplete understanding of the molecular pathways involved in EV trafficking. Moreover, there is a lack of pharmacological tools capable of selectively modulating these processes. Despite these limitations, the clinical application of EVs as biomarkers appears to be a more feasible near-term objective. Since EVs reflect the molecular state of their cells of origin, their concentration and molecular content offer valuable insights into disease progression and prognosis, particularly in neurological conditions where direct access to affected tissue is highly restricted. EVs can be readily isolated from peripheral fluids like blood, offering a minimally invasive diagnostic alternative. The potential of EVs as therapeutic delivery systems in neurological diseases is a promising but still early-stage area of investigation. Preliminary studies offer encouraging results, but extensive preclinical work is still required to determine optimal delivery routes, therapeutic cargoes, targeting mechanisms, and biodistribution. Notably, progress in the oncology field provides a valuable roadmap, suggesting that EV-based therapies could one day become viable options for treating neurological disorders as well. In conclusion, while substantial technical and biological challenges remain, the field of EV research holds considerable promise. With continued advancements, EVs could soon play a dual role in neurodegeneration, as both diagnostic biomarkers and innovative therapeutic tools, offering new hope for understanding and treating NMDs.